findmyKOL
Clinical trialNCT02454842TerminatedPhase 2Interventional

Study for Treatment With TH-4000 (Tarloxotinib) in Epidermal Growth Factor Receptor (EGFR) Mutant, T790M-negative Non-small Cell Lung Cancer (NSCLC) Patients

SponsorRain Oncology IncEnrollment21NSCLCNon-small Cell Lung CancerNon-squamous NSCLC
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This phase 2 study is designed to evaluate the safety and activity of TH-4000 a hypoxia-activated prodrug, in patients with EGFR-Mutant, T790M-Negative, Advanced NSCLC.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

12 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Australia
  • Peter Maccullum

    Melbourne, Victoria, Australia

United States
  • University of Southern California-Norris

    Los Angeles, California, United States

  • St. Joseph Heritage Healthcare

    Santa Rosa, California, United States

  • University of Colorado Cancer Center

    Aurora, Colorado, United States

  • Georgetown University Medical Center

    Washington D.C., District of Columbia, United States

  • Walter Reed National Military Medical Center

    Bethesda, Maryland, United States

  • University of North Carolina Lineberger Cancer Center

    Chapel Hill, North Carolina, United States

  • University of Pennsylvania-Abramson Cancer Center

    Philadelphia, Pennsylvania, United States

  • University of Pittsburgh Medical Center

    Pittsburgh, Pennsylvania, United States

  • Vanderbilt-Ingram Cancer Center (vicc)

    Nashville, Tennessee, United States

  • Ut Southwestern Medical Center

    Dallas, Texas, United States

  • Swedish Cancer Institute

    Seattle, Washington, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

TH-4000
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
30 Jun 2015
Primary completion
31 Jan 2017
Completion
31 Jan 2017
Last update posted
12 Jan 2023
Registered enrollment
21
Registry id
NCT02454842
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.